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Abstract
The swine-origin H1N1 inﬂuenza A virus (pH1N1(2009)) started to circulate worldwide in 2009, and cases were notiﬁed in a number
of sub-Saharan African countries. However, no epidemiological data allowing estimation of the epidemic burden were available in this
region, preventing comprehensive comparisons with other parts of the world. The CoPanFlu-Mali programme studied a cohort of 202
individuals living in the rural commune of Dioro (southern central Mali). Pre-pandemic and post-pandemic paired sera (sampled in 2006
and April 2010, respectively) were tested by the haemagglutination inhibition (HI) method. Different estimates of pH1N1(2009) infection
during the 2009 ﬁrst epidemic wave were used (increased prevalence of HI titre of ‡1/40 or ‡1/80, seroconversions) and provided con-
vergent attack rate values (12.4–14.9%), the highest values being observed in the 0–19-year age group (16.0–18.4%). In all age groups,
pre-pandemic HI titres of ‡1/40 were associated with complete absence of seroconversion; and geometric mean titres were <15 in indi-
viduals who seroconverted and >20 in others. Important variations in seroconversion rate existed among the different villages investi-
gated. Despite limitations resulting from the size and composition of the sample analysed, this study provides strong evidence that the
impact of the pH1N1(2009) ﬁrst wave was more important than previously believed, and that the determinants of the epidemic spread
in sub-Saharan populations were quite different from those observed in developed countries.
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Introduction
A new swine-origin variant of H1N1 inﬂuenza A virus
(pH1N1(2009), referred to here as pH1N1) was ﬁrst identi-
ﬁed in Mexico and the USA in March and early April 2009,
and secondarily circulated worldwide, reaching pandemic alert
level 6 on 11 June 2009. A global estimate of the number of
cases is difﬁcult to provide, given the number of mild or
asymptomatic cases and the absence of epidemiological data
from many regions of the world. It was probably in the order
of magnitude of several hundreds of million cases in 2009 and
early 2010. Whereas data regarding the spread of the virus in
the Americas, Europe and a number of Asian countries have
been documented [1], the impact of the pandemic in sub-Sah-
aran Africa remains poorly assessed. During the ﬁrst epidemic
wave, the circulation of the new variant was reported in the
literature in Kenya and South Africa [2–4], and by May 2010
cases had been notiﬁed in more than 35 countries by the
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WHO Pandemic (H1N1) 2009 surveillance system in the
African Region [5]. In the sub-Saharan region, the highest
numbers of conﬁrmed cases were in South Africa (12 640),
Tanzania (770), Ghana (720), Rwanda (524), Kenya (417), and
Senegal (325). Forty cases were reported in Mali.
However, no epidemiological data allowing the estimation
of the epidemic burden in sub-Saharan Africa were available.
Incomplete epidemiological data and the limited recourse to
speciﬁc inﬂuenza diagnosis currently available make any
comparison with other parts of the world extremely difﬁcult.
As part of the CoPanFlu-Mali programme, we carried out
the ﬁrst seroepidemiological evaluation of the pH1N1
pandemic in sub-Saharan Africa by studying a rural area
located in the southern central part of Mali.
Materials and Methods
Ethics statement
Study protocol collection was approved by the Institut
National de Recherche en Sante´ Publique (Ministry of Health,
Bamako, Mali) ethical committee. The approved informed
consent document was translated into the Bambara local
language and recorded on audiotape. The tape was played
for each participant before written consent was obtained
(ﬁngerprint).
Study population and data collection
The Malian Millennium village project provided sera from a
cohort of 202 subjects followed since 2006, before the epi-
demic started. Fig. 1 shows the locations of the different vil-
lages investigated in the Commune of Dioro (Se´gou Region),
located 240 km from Bamako, the capital city of Mali. Sam-
pling was performed from eight research villages (marked
with yellow triangles in Fig. 1). The distribution in the differ-
ent villages is indicated in Table 3.
This sampling was dependent on the previous Malian Mil-
lennium village project study and on the concrete possibility
of obtaining paired sera from the same individuals. It should
be noted that the number of individuals in the 10–19-year
age group who could be sampled during the 2010 campaign
was low (4%), explaining why numbers were lower than
expected in the 0–19-year age group and slightly higher in
the 20–29-year and 30–39-year age groups, in comparison
with the general Malian population and that of the villages
included in the study. The collection of sera sampled in 2006
was matched with a second set of sera from the same sub-
jects obtained in April 2010 under similar conditions. The
202 individuals recruited were aged 4–53 years in 2010
(male/female sex ratio = 0.96), matching the Malian age dis-
tribution, in which c. 95% of individuals are younger than
60 years and the sex ratio is 0.95. The global distribution of
age groups is shown in Table 1.
Laboratory methods
Venous blood samples were centrifuged within 2 h. Serum
was aliquoted in cryotubes and immediately stored in liquid
nitrogen containers until the end of the sampling campaign,
and ﬁnally stored at )80C.
These paired samples were used to estimate the serocon-
version rate between 2006 and 2010 and examine the circu-
lation of pH1N1 according to age group. They were tested
with a standard haemagglutination inhibition (HI) technique
adapted to the detection and quantiﬁcation of antibodies
against pH1N1 [6]. Brieﬂy, the antigen was made of 5.3 hae-
magglutinating units of non-inactivated virus, strain OPYFLU-
1 (a pH1N1 strain isolated from a young adult male patient
returning from Mexico in early May 2009 [7]). This strain is
FIG. 1. Location of villages studied in
Mali. The eight villages are in the cluster
of villages being researched for the Mil-
lennium Project Village of Tiby, Dioro
(Mali). Villages selected for research are
represented by yellow triangles.
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genetically closely related to strains A/Engl/195/2009(H1N1v)
and A/California/7/2009, which both include a number of
genetic markers (neuraminidase 106V and 248N; haemagglu-
tinin 220S) characteristic of viruses that circulated at the
very beginning of the pandemic [7]. Subsequent fully auto-
mated HI assays were performed in a BSL3 environment
(Marseille Medical University), with two-fold dilutions (1/10–
1/1280) of sera and group O human erythrocytes [6].
Statistical analysis
The seroprevalence of pH1N1 antibodies was calculated as
the percentage with antibody titres of ‡1/40 or ‡1/80. The
increase in the prevalence of HI titres of ‡1/40 and ‡1/80
between 2006 and 2010 was indicated as D ‡ 1/40 and
D ‡ 1/80, respectively. The increase in geometric mean titres
(GMTs) between 2006 and 2010 was indicated as DGMT.
Seroconversion was deﬁned as a four-fold or greater
increase in antibody titres.
For comparison of seroprevalence between 2006 and
2010, the McNemar chi-square for matched pairs was used.
For comparison of the GMTs between 2006 and 2010, the
Wilcoxon matched-pairs signed ranks test was used. For
comparison of the GMTs between seroconverters and non-
seroconverters, the Wilcoxon signed rank test was used.
GMTs were calculated by assigning a titre of 5 to speci-
mens in which no HI antibody was detected. The log trans-
formation used was as follows: log HI titre = log2 (HI titre/
5). An unbiased estimate of the GMT can be obtained by a
statistical method that originates from the analysis of survival
data (maximum likelihood estimation for censored observa-
tions). The maximum likelihood estimate of the GMT of
truncated HI titres and its conﬁdence interval were obtained
TABLE 1. Distribution of the population studied based on
age group
Age group (years)
N 0–19 (%) 20–39 (%) 40–59 (%) >59 (%)
Mali c. 14 million 58.44 23.18 12.76 5.62
Villages
investigated
15 682 54.92 28.57 11.41 5.11
Population
studied
202 43.07 35.15 21.78 –
TABLE 2. Seroprevalence and seroconversion rates in age groups based on pH1N1 HI analysis
Age group (years) N
HI ‡ 1/40
2006 (% (95% CI)) 2010 (% (95% CI)) D ‡ 1/40 p-valuea
(A)
All age groups 202 16.8 (11.9–22.6) 29.2 (22.9–35.8) 12.4 0.003
4–19 87 12.6 (6.5–21.5) 31.0 (21.6–41.9) 18.4 0.005
20–53 115 20.0 (13.1–28.5) 27.8 (19.9–37.0) 7.8 0.1
Age group (years) N
HI ‡ 1/80
2006 (% (95% CI)) 2010 (% (95% CI)) D ‡ 1/80 p-valuea
(B)
All age groups 202 3.5 (1.4–7.0) 16.3 (11.5–22.2) 12.8 <0.0001
4–19 87 3.5 (0.7–9.8) 19.5 (11.8–29.4) 16.0 0.001
20–53 115 3.5 (0.9–8.7) 13.9 (8.2–21.6) 10.4 0.002
Age group (years) N
GMT
2006 (% (95% CI)) 2010 (% (95% CI)) DGMT p-valueb
(C)
All age groups 202 21.5 (19.6–23.5) 28.6 (25.7–31.6) 7.1 <0.0001
4–19 87 20.7 (18.2–23.5) 30.5 (25.8–35.5) 9.8 0.0002
20–53 115 22.1 (19.4–24.9) 27.2 (23.7–31.1) 5.1 0.01
Age group
(years)
Seroconversion rate among: GMT 2006 among:
Individuals with 2006 HI
titre of <1/40 (% (95% CI))
Individuals with 2006
HI titre of ‡ 1/40 (%)
All groups
(% (95% CI))
Seroconverters
(% (95% CI))
Others
(% (95% CI))
p-valuec
(D)
All age groups 17.9 (12.4–24.5) 0.0 14.9 (10.3–20.5) 12.0 (11.5–12.4) 22.5 (20.3–24.8) 0.01
4–19 21.1 (12.5–31.9) 0.0 18.4 (10.9–28.1) 12.3 (11.6–13.0) 21.1 (18.0–24.5) 0.6
20–53 15.2 (8.6–24.2) 0.0 12.2 (6.8–19.6) 12.0 (undetermined) 23.5 (20.6–26.6) 0.005
GMT, geometric mean titre; HI, haemagglutination inhibition.
aMcNemar’s test for matched data.
bWilcoxon matched-pairs signed ranks test.
cWilcoxon signed ranks test.
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using the PROC LIFEREG in the statistical software package
SAS [8].
All data analyses were performed with the statistical software
package SAS version 9.1.3 (SAS Institute, Cary, NC, USA).
Results
Different estimates of the number of pH1N1 infections could
be established from the available dataset:
1. A ﬁrst ‘standard’ estimate was based on the comparison
of HI titres of ‡1/40 in 2006 and 2010 (D ‡ 1/40;
Table 2A). It indicated a signiﬁcant increase in the sero-
prevalence of 12.4%, which was greater in the <20-year
age group that in the ‡20-year age group (18.4% and
7.8%, respectively, p 0.02). Fig. 2 shows the seropreva-
lence by age group and for the overall population.
2. Titres of >1/40 were infrequent in the pre-epidemic per-
iod (3.5%, 95% CI 1.4–7.0), but reached 16.3%
(95% CI 11.5–22.2) (p <0.0001, McNemar test) in the
post-epidemic panel, providing direct evidence for the
circulation of pH1N1. The D ‡ 1/80 value (which repre-
sents the increase in prevalence of HI titres of ‡1/80
between 2006 and 2010, i.e. 12.8%) was used as a sec-
ond estimate of the number of pH1N1 infections: it was
in the same order of magnitude as D ‡ 1/40, and
reached signiﬁcant values in the general population
(p 0.001 and p 0.002 in the 4–19-year and 20–53-year
age groups, respectively; see Table 2B).
3. The impact of pH1N1 infection was further evaluated by
a third method, i.e. by analysing the rate of documented
strict seroconversions (a minimum four-fold increase in
HI titre between pre-epidemic and post-epidemic sam-
ples) in the studied population (Table 2D). In agreement
with the results presented above, it was higher in
individuals under the age of 20 years (18.4%) than in
those over the age of 20 years (12.2%, with similar val-
ues for the 20–39-year and 40–53-year age groups; data
not shown).
Accordingly, all methods used (D ‡ 1/40, D ‡ 1/80, and
seroconversion rate) provided results in the same order of
magnitude, and therefore robust estimates of the infection
rates. The increase in the uncensored GMT faithfully fol-
lowed that of seroconversion rates in the age groups, and
indicated a signiﬁcant increase in all groups between 2006
and 2010 (Table 2C). Pre-epidemic GMT values were lower
in seroconverters than in others (Table 2D).
Important variations in seroconversion rate existed among
the different villages investigated (0–50%), with a lack of
independence between location and seroconversion (exact
Fisher test, p 0.046). These are detailed in Table 3.
Discussion
To date, there is little information available regarding the
spread of pH1N1 in populations living in rural areas, and
even less regarding sub-Saharan Africa. By October 2011,
more than 30 seroepidemiological studies of the pandemic
had been published in peer-reviewed scientiﬁc journals,
including studies performed in North America, Europe, Asia,
TABLE 3. Seroconversion rates in the eight villages studied
Villages n
Seroconversion
rate (%) 95% CI
Diarraka We`re` 7 0.0 –
Koı¨la Markala 40 7.5 1.6–20.4
Tiby II 19 10.5 1.3–33.1
Koı¨la Bamanan 65 12.3 5.5–22.8
Tiby I 38 15.8 6.0–31.1
We`na 13 23.1 5.0–53.8
Kolomi 10 30.0 6.7–65.3
Tiby We`re` 10 50.0 18.7–81.3
Independence test (Fisher exact test, p 0.046).
FIG. 2. Prevalence of pH1N1 HI titres
of ‡1/40 in 2006 and 2010, for the
overall population and according to age
group.
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and Oceania. No study was performed in Africa, very limited
information was made available from rural populations, and
only a few studies were based on paired sera sampled before
and after the pandemic. In addition, the comparability of
studies is limited by differences in technical HI protocols and
endpoint analysis methods [9]. Accordingly, studying a rural
area of southern central Mali, with the same HI protocol as
in previously reported studies in other regions of the world
(metropolitan France and the southeast Indian Ocean [6,10]),
was of great epidemiological interest.
The population investigated has obvious limitations in
terms of epidemiological representativeness: it is limited (202
individuals), the 10–19-year age group is under-represented,
and, given that the prevalence differed from village to village,
the extrapolation of results to larger populations is delicate.
However, obtaining paired sera sampled in 2006 and April
2010 in a programme providing strong guarantees in terms
of ethical procedures as well as quality of biological samples
and collected information constituted a unique opportunity
to perform, in a sub-Saharan rural population, a seroepidemi-
ological investigation of the ﬁrst pH1N1 wave, which
occurred in 2009. In Mali, the ﬁrst case was ofﬁcially
reported by the WHO on 9 January 2010 [11]. As of April
2010, the date corresponding to the beginning of our study,
29 cases had been reported by the WHO [12]. The ﬁnal
count for infected cases was 40 in the country [5] (3 May
2010). No deaths were reported.
HI analyses showed that, in the pre-epidemic period, anti-
bodies cross-reacting with pH1N1 antigen could be detected
at titres of ‡1/40 in a signiﬁcant proportion of individuals
(16.8%; Table 2A). Given the age groups examined, it is unli-
kely that such antibodies were acquired following previous
contact with strains related to the 1918 Spanish ﬂu original
virus (as proposed in the case of individuals over 60 years of
age). It is more likely that they denote cross-reactivity with
recent seasonal H1N1 inﬂuenza strains, as previously
observed in the younger age classes of Western countries
(see [13,14] for reviews). Importantly, high pre-pandemic ti-
tres (‡1/80) were rare (<4%; Table 2B); that is, cross-reactiv-
ity with seasonal H1N1 resulted in low-titre (1/40) pH1N1
HI results. This implies, in accordance with previous observa-
tions in metropolitan France [6], that populations commonly
exposed to seasonal H1N1 inﬂuenza did not develop, in the
pre-epidemic period, high-titre cross-reactive antibody
responses to pH1N1. Accordingly, the increased prevalence
of pH1N1 HI titres of ‡1/80 between the pre-epidemic and
post-epidemic periods (D ‡ 1/80 = 12.8%; Table 2B) is
expected to provide a speciﬁc picture of the impact of recent
pH1N1 infections in this population. In addition, this value is
similar to other estimates of the attack rate based on the
D ‡ 1/40 value or the number of strict seroconversions in
paired sera (12.4% and 14.9%, respectively; Table 2).
Where pH1N1 infection occurred, the most susceptible
parts of the population identiﬁed by our three methods were
(Table 2): (i) the 0–19-year age group, as previously reported
in other parts of the world; and (ii) individuals with a low
titre of cross-reacting antibodies in the pre-pandemic period.
Regarding the latter item, serological data revealed that, in
all age groups, pre-epidemic GMT values were <15 in individ-
uals who seroconverted and >20 in others (Table 2D). This
result is corroborated by the observation that, in all age clas-
ses, individuals with HI titres of ‡1/40 in the pre-epidemic
period had complete protection against infection (as esti-
mated by seroconversion), whereas the seroconversion rates
reached 21.1% and 15.2% in patients with titres of <1/40
belonging to the 0–19-year and 20–53-year age groups,
respectively. These ﬁndings are in agreement with those
from a study performed in Reunion Island [10], using the
same HI protocol, and suggest that acquisition of a sufﬁcient
titre of cross-reacting antibodies against seasonal inﬂuenza
viral strains may have been protective against pH1N1 infec-
tion. They also conﬁrm that some epidemiological determi-
nants of infection are speciﬁc to the youngest age class, as
pre-pandemic HI titres of <1/40 were associated with quite
different seroconversion rates in the 0–19-year and 20–53-
year age groups.
The population studied in the commune of Dioro mainly
comprised members of the farming community. No relation-
ship was identiﬁed between pH1N1 seroconversion and sex
or occupation. This population was extremely stable, with a
very few individuals travelling outside their region of origin
during the year preceding the 2010 investigation. The pro-
portion of individuals who experienced seroconversion ran-
ged from 0% to 50% according to the different villages
included in the analysis, with the highest seroconversion rate
being encountered in the village of Tiby We`re` (Table 3),
where the only two individuals (one adult and one 4-year-
old child) who had travelled signiﬁcantly over the last
12 months (i.e. to Niono, a village located 200 km away)
lived. The child presumably contaminated four individuals in
the same family, possibly initiating the outbreak.
This heterogeneous distribution of cases illustrates the
speciﬁc epidemiological pattern observed in such rural areas.
In contrast with what has previously been observed in most
developed countries (and in urban populations in general),
which are exposed to multiple viral entries because of
important population exchanges allowing rapid progression
of the pandemic, the geographical stability of the population
studied obviously limited the spread of the disease, and some
villages were not exposed to the epidemic wave.
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This also constitutes, in conjunction with the size of the
population studied, a serious limitation to the extrapolation
of these results. However, given the speciﬁc shape of the
Malian age distribution (nearly 60% of the population are
younger than 20 years), it is likely that the vast majority of
cases occurred in the 0–19-year age group (our data provide
estimates of >70%). In conclusion, the most careful estimates
indicate that pH1N1 circulated in this rural area in 2009, and
that the 40 conﬁrmed cases previously reported in Mali [5]
provide a very limited picture of the actual impact of the epi-
demic. Presumably, the attack rate in the rural area studied
was of an order of magnitude comparable with that of Wes-
tern countries (e.g. c. 12% in a French population, using the
same HI method [6]).
As the conditions in Mali are quite different from those
encountered in most regions of the world investigated previ-
ously, being characterized by a rural setting, a limited num-
ber of viral introductions, the probable importance of
intrafamilial spread, and the absence of speciﬁc preventive or
curative countermeasures, this study highlights the absolute
need to improve our knowledge of the epidemiology of viral
respiratory infections in sub-Saharan African countries.
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